The invention discloses a novel application of a fluorinated
camptothecin compound for resisting
bladder cancer activity, which is used for preparing a
medicine for treating
bladder cancer, and belongs to the field of biological medicines. The invention particularly relates to application in treatment of
bladder cancer. According to the determination of the
drug activity in different bladder
cancer cells, the bladder
cancer cells are compared with a common
drug cisplatin for treating bladder
cancer and commercialized
camptothecin drugs
topotecan and
irinotecan. The result shows that the fluorinated
camptothecin compound disclosed by the invention has relatively strong inhibitory activity on bladder cancer T24 and umuc3
cell strains. Wherein the activity of the W-16 is the best, and the IC50 values of the W-16 to bladder cancer T24 and umuc3
cell strains are 0.000307 uM and 0.000291 uM respectively, which are obviously superior to those of reference drugs such as cis-
platinum,
topotecan and
irinotecan. In addition, W-1, W-2, W-3, W-5, W-6, W-8, W-11, W-12, W-13, W-15 and W-18 also all exhibit superior or close activity to
control drugs for bladder cancer T24 and umuc3
cell lines. And W-4, W-7, W-9, W-14, W-17 and W-19 show better inhibition effects on the two tested
bladder cancer cell lines than
irinotecan. Therefore, the fluorinated camptothecin compound provided by the invention has a good application prospect in treatment of bladder cancer.